Research Analysts Offer Predictions for MCRB FY2025 Earnings

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Stock analysts at Chardan Capital increased their FY2025 earnings per share (EPS) estimates for shares of Seres Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biotechnology company will post earnings per share of ($0.57) for the year, up from their previous estimate of ($0.73). Chardan Capital currently has a “Buy” rating and a $1.25 target price on the stock. The consensus estimate for Seres Therapeutics’ current full-year earnings is ($0.38) per share.

Several other research analysts also recently weighed in on the stock. StockNews.com raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 6th. The Goldman Sachs Group dropped their price target on shares of Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a research note on Friday, March 14th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.00.

Seres Therapeutics Stock Performance

Seres Therapeutics stock opened at $0.72 on Thursday. The firm’s 50 day moving average price is $0.78 and its two-hundred day moving average price is $0.82. The firm has a market cap of $125.71 million, a price-to-earnings ratio of -3.13 and a beta of 2.19. Seres Therapeutics has a 1 year low of $0.54 and a 1 year high of $1.53.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in Seres Therapeutics by 42.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after acquiring an additional 222,771 shares during the period. FMR LLC raised its stake in shares of Seres Therapeutics by 0.6% in the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after purchasing an additional 140,096 shares in the last quarter. Providence Wealth Advisors LLC lifted its position in Seres Therapeutics by 29.2% in the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 22,250 shares during the period. State Street Corp lifted its holdings in shares of Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after acquiring an additional 43,700 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Seres Therapeutics by 22.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after buying an additional 255,014 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.